TD Cowen lowered the firm’s price target on Biogen to $300 from $305 and keeps an Outperform rating on the shares. The firm said they reported light Q4 revenue but cost savings drove an EPS beat and 2024 guidance includes flat product revenue and 1% EPS growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
